Today's Peptide News — September 21, 2026

A new bioRxiv preprint describes a retro-inverso peptide — built from D-amino acids in reversed sequence, so it mirrors the natural molecule — that targets the cross-alpha amyloid structure formed by a biofilm-building modulin peptide in Staphylococcus aureus. In the reported experiments the peptide blocks new amyloid fibril formation, triggers disassembly of pre-formed fibrils, and disperses established MRSA biofilm biomass in a dose-dependent way.

Because the retro-inverso design is resistant to proteases, the molecule should survive far longer in the body than a conventional peptide, a recurring obstacle for peptide therapeutics. Biofilms are what make MRSA infections on catheters, implants, and wounds so stubborn, since the matrix shields bacteria from both antibiotics and the immune system.

This is strong material for a PeptideWiki explainer on retro-inverso and D-peptide design: use it to walk through why mirroring a peptide buys stability, and how anti-biofilm peptides differ from classic membrane-lysing antimicrobial peptides.

Researchers report that hydrocarbon-stapled peptides derived from the BAD BH3 helix retain, and in some cases enhance, binding to BCL-2 proteins carrying the resistance mutations that blunt venetoclax and similar small-molecule inhibitors. Stapling locks the peptide into its active alpha-helical shape, improving stability and cell entry while preserving the broad contact surface a peptide makes with its target.

The finding matters because acquired resistance to BCL-2 inhibitors is a leading cause of relapse in leukemias and lymphomas, and the mutations that cause it often sit in the small pocket that a drug like venetoclax depends on. A peptide that grips the whole binding groove is less easily evaded by a single point mutation.

A good PeptideWiki angle is a piece on peptide stapling as a resistance-beating strategy: explain the mechanics of the staple, contrast a peptide's large interface with a small molecule's narrow pocket, and note why this is one of the clearest arguments for peptides in oncology.

A designed peptide that mimics a fragment of the chaperone protein Hsp90, dubbed beta-Hsp90, was shown to interfere with the aggregation of Tau, the protein whose tangles are a hallmark of Alzheimer's disease and other tauopathies. Rather than clearing plaques after they form, the peptide appears to act upstream by stabilizing Tau and preventing the misfolding cascade from getting started.

This is notable given how many anti-amyloid programs have targeted beta-amyloid with mixed results; a chaperone-mimicking peptide aimed at Tau offers a mechanistically different shot at neurodegeneration. It also illustrates a broader theme of borrowing sequences from the body's own protein-quality-control machinery to build therapeutics.

For PeptideWiki, this fits a short post on chaperone-derived peptides and Tau: define tauopathies briefly, explain how a peptide can act as a "folding coach," and situate it against the beta-amyloid antibody era.

A recent paper details a generative pipeline that designs and computationally validates therapeutic peptides aimed at ATP5A, a subunit of the mitochondrial ATP synthase implicated in glioblastoma metabolism. The workflow proposes novel peptide sequences, screens them for predicted binding and drug-like properties, and narrows to a shortlist for experimental follow-up.

Glioblastoma remains one of the hardest cancers to treat, and its reliance on mitochondrial energy production makes ATP5A an intriguing, less-explored target. The study is also a clean example of how generative models are compressing the early discovery timeline for peptides, moving from target to candidate list in silico.

A fitting PeptideWiki angle is an accessible explainer on AI-driven peptide design: describe what generative models actually generate, why peptides suit this approach, and the gap that still separates a computationally validated candidate from a validated drug.

Earlier this month the FDA published a cluster of warning letters aimed at online peptide vendors, citing unapproved new drugs and misbranding. The letters named products spanning the metabolic and research-peptide worlds, including semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31, PT-141, tesamorelin, ipamorelin blends, and bacteriostatic water sold for reconstitution.

The sweep underscores the regulatory gray zone around "research use only" peptide sales direct to consumers, and the agency's continued position that many widely marketed peptides are unapproved drugs. It lands amid a broader, unusually public tug-of-war over how accessible these compounds should be.

For PeptideWiki, this supports a straight news post on the legal status of consumer peptides: clarify what a warning letter does and doesn't do, and why "research only" labeling does not make a product legal to sell for human use.

In a closely watched July 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted narrowly — roughly 8 to 6 with an abstention — to recommend adding six of seven reviewed peptides to the list of substances allowed for pharmacy compounding. The peptides in question were BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax, several of which are favored in longevity and wellness circles.

The vote is advisory and not binding, and agency scientists cautioned that the compounds have not been shown safe and effective in the usual sense. It nonetheless signals momentum behind Health Secretary Robert F. Kennedy Jr.'s stated goal of loosening restrictions, and sits in tension with the same agency's warning-letter activity against sellers.

This is rich context for PeptideWiki entries on each named peptide: it justifies clear, evidence-first pages on BPC-157, MOTS-c, KPV, TB-500, Epitalon, and Semax that separate what the compounding debate is about from what the clinical evidence actually shows.

Retatrutide, an investigational triple agonist hitting the GIP, GLP-1, and glucagon receptors, continues to post the largest weight reductions yet seen in obesity trials, with Phase 2 results around the mid-20s in percent body-weight loss and Phase 3 readouts anticipated in the second half of 2026. A regulatory filing is expected late this year, with approval unlikely before 2027 or 2028.

The three-receptor design is the story: adding glucagon-receptor activity is thought to raise energy expenditure on top of the appetite suppression that GLP-1 and GIP provide, which may explain the outsized efficacy. If the Phase 3 numbers hold, retatrutide would reset the benchmark that semaglutide and tirzepatide established.

A useful PeptideWiki angle is a comparison post on mono-, dual-, and triple-agonist incretin peptides: explain what each receptor contributes and why stacking them appears to increase weight loss.

Researchers report that noninvasive imaging of the eye may help identify people at elevated risk of atrial fibrillation well before symptoms appear. The retina offers a rare direct window onto small blood vessels, and subtle vascular patterns there appear to track with future heart-rhythm problems.

If validated, retinal screening could become a low-cost, painless way to triage cardiovascular risk during a routine eye exam, catching a common and stroke-linked arrhythmia earlier than current practice allows.

A new analysis links heavy consumption of certain preservatives common in processed foods to substantially higher rates of high blood pressure and cardiovascular disease. The work adds to a growing body of evidence that specific additives, not just overall diet quality, may carry independent cardiovascular risk.

The findings are associational rather than proof of cause, but they strengthen the case for scrutinizing individual processed-food ingredients and for clearer labeling of the additives involved.

Analysis of ancient DNA reveals that the plague bacterium repeatedly returned to Europe for more than four centuries after the Black Death, evolving into new lineages and spreading along routes of trade, migration, and war. Rather than a single catastrophe, the record shows wave after wave of reintroduction and local adaptation.

The study reshapes how historians and epidemiologists think about the disease's long tail, and offers a vivid case study in how a pathogen persists and diversifies across human populations over centuries.